
LCTX Stock Forecast & Price Target
LCTX Analyst Ratings
Bulls say
Lineage Cell Therapeutics Inc. demonstrated significant progress in its clinical programs, notably achieving sustained visual acuity gains in Phase 1/2a trials for its OpRegen therapy, which supports a positive outlook for its development in treating geographic atrophy. The successful execution of multiple cGMP production runs and the recognition of a $5 million milestone payment from Roche highlight the company's growing credibility and operational capabilities. Additionally, Lineage's revenue surged to $6.6 million in Q4 2025, a substantial increase from $2.9 million in the prior year, primarily driven by collaboration contracts, indicating a strong trajectory for future growth and pipeline expansion.
Bears say
Lineage Cell Therapeutics Inc's financial outlook appears negative due to the inherent risks associated with its clinical-stage status and the uncertainty surrounding the commercial viability of its therapies, including its core programs like OpRegen and OPC1. The company’s reliance on a proprietary manufacturing platform, AlloSCOPE, may not adequately offset the high costs and challenges associated with development and regulatory approval processes. Additionally, potential delays in clinical trials or failure to secure necessary funding could further jeopardize its financial stability and growth prospects.
This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LCTX Analyst Forecast & Price Prediction
Start investing in LCTX
Order type
Buy in
Order amount
Est. shares
0 shares